Tübingen's messenger RNA vaccine and drug developer's latest round includes a $171m investment by strategic partner GlaxoSmithKline.

CureVac, a Germany-based RNA therapy spinout of Eberhard Karls University of Tübingen, closed a $640m financing round on Tuesday that included $171m from pharmaceutical firm GlaxoSmithKline, which signed a strategic partnership with it this week. The round includes $343m in the form of the funding commitment made by German development bank KfW last month and…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.